M Kitaichi
Boston University
10 Papers
30 Citations
M Kitaichi is an academic researcher from Boston University. The author has contributed to research in topics: Medicine & Usual interstitial pneumonia. The author has an hindex of 6, co-authored 10 publications.
Chat about Author
Papers
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
William D. Travis,Ulrich Costabel,David M Hansell,Talmadge E. King,David A. Lynch,Andrew G. Nicholson,Christopher J. Ryerson,Jay H. Ryu,Moisés Selman,Athol U. Wells,Jurgen Behr,Demosthenes Bouros,Kevin K. Brown,Thomas V. Colby,Harold R. Collard,Carlos Robalo Cordeiro,Vincent Cottin,Bruno Crestani,Marjolein Drent,Rosalind F. Dudden,Jim Egan,Kevin R. Flaherty,Cory M. Hogaboam,Yoshikazu Inoue,Takeshi Johkoh,Dong Soon Kim,M Kitaichi,James E. Loyd,Fernando J. Martinez,Jeffrey L. Myers,Shandra Protzko,Ganesh Raghu,Luca Richeldi,Nicola Sverzellati,Jeffrey J. Swigris,Dominique Valeyre +35 more
TL;DR: This update is a supplement to the previous 2002 IIP classification document and outlines advances in the past decade and potential areas for future investigation.
•Journal Article
ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders.
Gary W. Hunninghake,Ulrich Costabel,Masayuki Ando,Robert P. Baughman,Jean-François Cordier,du Bois R,A. Eklund,M Kitaichi,Lynch J,Rizzato G,Cecile S. Rose,Olof Selroos,Gianpietro Semenzato,Om P. Sharma +13 more
1.3K
Usual Interstitial Pneumonia and Nonspecific Interstitial Pneumonia with and without Concurrent Emphysema: Thin-Section CT Findings
TL;DR: According to multivariate analysis, the CT feature that helped best differentiate UIP from NSIP in patients with emphysema was traction bronchiolectasis, which influenced the distinction between UIP and NSIP.
138
•Journal Article
Polymyxin-B hemoperfusion for acute exacerbation of idiopathic pulmonary fibrosis: serum IL-7 as a prognostic marker.
Kazunobu Tachibana,Yoshikazu Inoue,Akihide Nishiyama,Chikatoshi Sugimoto,Akiko Matsumuro,Masaki Hirose,M Kitaichi,Masanori Akira,Toru Arai,Seiji Hayashi +9 more
TL;DR: Serum levels of Interleukin (IL)-7, an anti-fibrotic cytokine, in survivors at day 30 following PMX-DHP therapy significantly increased after the treatment, compared to serum levels of non-survivors at day30 after the therapy, which did not demonstrate a significant change.
50
•Journal Article
Lymphatic manifestations of lymphangioleiomyomatosis.
TL;DR: Molecular targeted therapy with sirolimus stabilizes lung function, is anti-lymphangiogenic, and is highly effective for the lymphatic and chylous complications of LAM.